PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7494384-0 1995 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Fluvoxamine 47-58 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 0-15 19958758-0 2010 Involvement of the 5-HT(1A) receptor in the anti-immobility effects of fluvoxamine in the forced swimming test and mouse strain differences in 5-HT(1A) receptor binding. Fluvoxamine 71-82 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 19-36 19958758-4 2010 The anti-immobility effects of fluvoxamine in DBA/2 mice were inhibited by the 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide (WAY 100635). Fluvoxamine 31-42 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 79-96 19958758-6 2010 These results suggest that fluvoxamine-induced antidepressant-like effects in DBA/2 mice are mediated by the 5-HT(1A) receptor. Fluvoxamine 27-38 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 109-126 19958758-10 2010 These results suggest that, although the anti-immobility effects of fluvoxamine in DBA/2 mice are mediated by the 5-HT(1A) receptor, strain differences in 5-HT(1A) receptor binding are not related to variation in immobility time and responses to fluvoxamine. Fluvoxamine 68-79 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 114-131 9888626-9 1998 We conclude that 5-HT1A receptors are involved in the stimulus properties of both fluvoxamine and fluoxetine, that 5-HT2C receptors are involved in fluvoxamine and especially fluoxetine, and, based primarily on the cross-comparison tests, that the two SSRIs have somewhat different stimulus properties. Fluvoxamine 82-93 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 17-23 7494384-10 1995 However, the 5-HT1A antagonist NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine) inhibited the suppressive effect of fluvoxamine on the marble-burying. Fluvoxamine 135-146 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 13-19 7494384-11 1995 From these results, the 5-HT1A-receptor subtype may be involved in the suppressive effect of fluvoxamine on the marble-burying, but the 5-HT2-receptor subtype is not involved in this effect. Fluvoxamine 93-104 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 24-39 7494385-7 1995 On the other hand, the 5-HT1A antagonist NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine) potentiated the effect of fluvoxamine on forced-swimming. Fluvoxamine 135-146 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 23-29 7494385-8 1995 It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming. Fluvoxamine 82-93 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 32-38 7494385-8 1995 It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming. Fluvoxamine 141-152 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 32-38 7494385-8 1995 It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming. Fluvoxamine 141-152 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 99-105 27987210-9 2017 The effect of fluvoxamine was blocked by a 5-HT1A or a sigma1 receptor antagonist, and co-administration of the sigma1 receptor agonist (+)-SKF-10047 and the 5-HT1A receptor agonist osemozotan mimicked the effect of fluvoxamine. Fluvoxamine 14-25 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 43-49 28529139-4 2017 We also suggest that the anti-anhedonic effect of fluvoxamine is mediated by combined activation of the 5-HT1A and sigma1 receptors and it is associated with activation of prefrontal dopaminergic system. Fluvoxamine 50-61 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 104-110 25727963-0 2015 Role of the 5-HT1A autoreceptor in the enhancement of fluvoxamine-induced increases in prefrontal dopamine release by adrenalectomy/castration in mice. Fluvoxamine 54-65 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 12-18 25727963-1 2015 We have found that fluvoxamine-induced increases in prefrontal dopamine release are enhanced by adrenalectomy/castration and 5-HT1A receptors are involved in the enhancement. Fluvoxamine 19-30 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 125-131 27339616-1 2016 RATIONALE: We previously reported that the fluvoxamine-induced increase in prefrontal dopamine levels is enhanced by adrenalectomy/castration (which results in circulating neurosteroid deficiency), via combined activation of serotonin1A (5-HT1A) and sigma1 receptors. Fluvoxamine 43-54 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 238-244 25252797-4 2014 Fluvoxamine (10 - 100 muM) concentration-dependently suppressed both monosynaptic A-fiber- and C-fiber-mediated EPSCs, which were attenuated by the selective 5-HT1A receptor antagonist WAY100635. Fluvoxamine 0-11 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 158-164 25252797-8 2014 These results suggest that fluvoxamine reduces excitatory synaptic transmission from primary afferent fibers via presynaptic mechanisms involving 5-HT1A and/or 5-HT3 receptors, which may contribute to its analgesic effects. Fluvoxamine 27-38 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 146-152